8 July 2026
Our impact in numbers
14
new drugs to market
1.5m+
life years* gained by cancer patients through drugs Cancer Research Horizons helped get to market
170+
early-phase clinical trials initiated
8 in 10
NHS cancer patients treated with cancer drugs receive a drug that Cancer Research UK helped develop
28m+
courses of treatment for cancers through drugs Cancer Research Horizons helped get to market
£600m+
reinvested in research from royalties and IP revenue
150+
active license agreements
£3.55bn+
raised by our start-up portfolio
95+
start-ups supported
24
exits
Portfolio company Myricx Bio is set to be acquired by Novartis in a deal worth up to $1.5bn
Impact news
From early funding by Cancer Research UK, to groundbreaking research by Ed Tate, to one of Europe's largest Series A raises of 2024, including investment from us, Myricx Bio has transformed an unconventional idea into pioneering science, developing a first-in-class ADC payload platform designed to overcome key limitations of existing ADCs, with potential across multiple solid tumour types.
Latest news
Discover how we're accelerating breakthroughs
Our annual reviews detail our research progress, commercial partnerships, start-ups and financial stewardship. We also champion responsible research through the UCL LEAF framework and report annually on our gender and ethnicity pay gap.
Do you want to help bring forward the day when all cancers are conquered?
We want to hear from researchers, entrepreneurs, partners and investors.
*Expressed as quality-adjusted life years (QUALYs).